14 results about "Vaccine research" patented technology

The invention discloses an antigen LARP1 of cysticercus bovis and application of the antigen LARP1, and belongs to the technical field of biochemistry. The invention aims to provide a detection method and a treatment and prevention method for cysticercosis bovis. The invention provides an antigen of cysticercus bovis. The amino acid sequence of the antigen of cysticercus bovis is as shown in SEQ ID NO. 4. And a new candidate antigen is provided for research and development of novel vaccines, development of specific diagnostic reagents and the like.

The present application relates to the technical field of biotechnology, in particular to a monoclonal antibody against A29L protein of monkeypox virus and application thereof. The present application prepares the monoclonal antibody against A29L protein of monkeypox virus, and through optimization of antibody screening and expression technology, the antibody with high affinity and high specificity is screened, and then a new tool is provided for rapid detection, effective neutralization and treatment of monkeypox virus, and an important immunological basis is provided for vaccine research and development and treatment scheme design of monkeypox virus.

The invention discloses application of carfilzomib in preparation of a medicine for preventing and treating Nipah virus, and belongs to the technical field of medicine. The method mainly aims at ubiquitination modification of nipah virus M protein, the carfilzomib is used for inhibiting a host proteasome path, free ubiquitination factors in cells are depleted to achieve the effect of inhibiting ubiquitination of the M protein, then nucleoplasm shuttle of the M protein is inhibited, replication of the nipah virus is inhibited, and the effect is good. At present, most of research and development of virus medicines and vaccines are designed or modified aiming at viruses, a new thought is provided for research and development of medicines and vaccines in the future, and a new application is also provided for Carfilzomib.

The invention belongs to the technical field of in-vitro transcription, and particularly discloses a 5 'UTR element with a protein expression enhancing function, an expression vector and application. The 5 'UTR is selected from any one of an SPP1d element, a TSPAN1u1 element and an SPP1d-TSPAN1u1 series element; the nucleotide sequence of the SPP1d element is as shown in SEQ ID NO: 1, the nucleotide sequence of the TSPAN1u1 element is as shown in SEQ ID NO: 2, and the nucleotide sequence of the SPP1d-TSPAN1u1 tandem element is as shown in SEQ ID NO: 3. The 5 'UTR element can significantly improve translation efficiency, has a wide enhancement effect on functional protein expression, is high in biological safety, and provides a standardized and high-performance translation regulation tool for the fields of efficient recombinant protein production, gene therapy vector optimization, vaccine research and development and the like.

The invention provides an ELISPOT (Enzyme-Linked Immunospot Assay) analysis method for detecting IFN-gamma and IL-2 secretion, which comprises the following steps: activating an ELISPOT plate, washing, adding IFN-gamma and IL-2 capture antibody coating with specific concentration, and staying overnight at 4 DEG C; recovering and counting target sample cells, resuspending the target sample cells according to a certain concentration, and adding the target sample cells into coated plate holes; incubating for more than 16 hours in an environment of 37 DEG C and 5% COC; washing the incubated plate, adding IFN-HRP and IL-2-ALP detection antibodies, and incubating at room temperature for 2 hours; after washing, adding a blue developing solution for developing for 10-15 minutes; adding a red developing solution, incubating for 10-15 minutes, and stopping developing; according to the method, T cell subset identification and multifunctional analysis can be carried out, in the early stage of vaccine research and development, due to the fact that target positive population is small, the number of obtained PBMC cells is small, two-factor detection can detect different cell factor reaction frequencies and locate different cell populations and subtypes at the same time, and comparison of two-factor data is beneficial to finding out population immune differences; and scientific research and vaccine development are promoted.

An adenoviral vector carrying a trichinella spiralis CLP gene, a construction method therefor, and an application thereof, relating to the technical fields of genetic engineering and recombinant viral vaccines. In order to solve the technical problem of existing trichinella spiralis vaccines being administered as a 2 to 3 dose series and failing to provide long-term efficacy, the present invention uses a trichinella spiralis CLP protein as an antigen, and integrates a gene encoding the CLP protein into an adenovirus vector by means of recombinant DNA technology, so as to obtain a recombinant adenoviral vector; the recombinant adenovirus vector is then transfected into mammalian cells and subjected to packaging and amplification processes to obtain a recombinant adenovirus, with multiple experiments then conducted to confirm the recombinant adenovirus. In addition, animal immunization experiments demonstrate that immunizing mice with recombinant adenovirus rAd5TsCLP achieves effective protection against trichinella spiralis infection. The present invention lays a foundation for subsequent trichinella spiralis vaccine research.

The invention discloses a respiratory virus inactivation data-driven modeling prediction control method, which relates to the technical field of biological medicine, and comprises the following steps: acquiring initial virus characteristic data from a virus surface structure database through molecular dynamics simulation, and processing to obtain a structure change matrix of viruses under different inactivation conditions; performing feature extraction on virus characteristics and antibody binding sites by adopting a support vector machine classifier according to the structure change matrix, and determining a potential unexpected interaction site set; according to the respiratory virus inactivation data-driven modeling prediction control method, the scientificity and stability of inactivation process parameter determination are effectively improved, the safety risk caused by improper inactivation conditions is reduced, the process optimization period is shortened, the experiment cost is reduced, the good immune effectiveness is maintained while the virus inactivation safety is guaranteed, and the method is suitable for popularization and application. Therefore, the practical application requirements in vaccine research and development and virus prevention and control can be better met.

The present invention relates to the field of biological vaccine research and development technology, and in particular, to a VSV vector-based highly pathogenic H5 subtype avian influenza inactivated vaccine and a method for preparing same. The method comprises: using a vesicular stomatitis virus with the deletion of the surface envelope protein gene as a vector, inserting the NA gene and the HA gene of an H5 subtype highly pathogenic avian influenza virus strain between the M gene and the L gene of the vector in the form of an expression cassette, and acquiring a recombinant virus by means of rescue via reverse genetic technology; inoculating the recombinant virus into susceptible cells, culturing for replication and proliferation, and then harvesting a viral solution; inactivating the viral solution to acquire an inactivated viral solution; and adding the inactivated viral solution to a pharmaceutically or veterinarily acceptable carrier, excipient, medium, or adjuvant to acquire an inactivated vaccine. The provided H5 subtype avian influenza inactivated vaccine can induce a high hemagglutination inhibition titer of avian influenza virus on day 21 after chick immunization. The provided inactivated vaccine has good safety and immunogenicity.

The invention discloses a baculovirus expression vector as well as a construction method and application thereof. The vector takes pFastBacDual as a skeleton, 2-9 repetitive BS sequence modification promoters are connected in series to the downstream of a polh promoter, an extremely advanced transcription factor VLF-1 gene is introduced, and the two components synergistically enhance the transcriptional activity. According to the invention, three types of recombinant vectors pBSX-eGFP, pBSX-eV and pBSX-GV are constructed, and the optimal combination is determined as overexpression of two repeated BS sequences and VLF-1, so that the expression quantity of the target protein can be increased. The vector construction process is standardized, enzyme cutting sites such as BamHI and EcoRI are reserved, and high-expression protein can be obtained after Sf9 cells are transfected and cultured for 4-5 days. The recombinant protein expression efficiency of a baculovirus expression system is improved, the advantages of correct folding and post-translational modification of the recombinant protein are reserved, and the method is suitable for large-scale industrial recombinant protein production scenes such as biopharmacy and vaccine research and development and has important application value.

The present invention provides a neutralizing monoclonal antibody 10G8 for recognizing CV-A6. Six CDR regions of the monoclonal antibody 10G8 are specifically as follows: (1) the amino acid sequence of a heavy chain CDR1 is set forth in SEQ ID NO. 1; (2) the amino acid sequence of a heavy chain CDR2 is set forth in SEQ ID NO. 2; (3) the amino acid sequence of a heavy chain CDR3 is set forth in SEQ ID NO. 3; (4) the amino acid sequence of a light chain CDR1 is set forth in SEQ ID NO. 4; (5) the amino acid sequence of a light chain CDR2 is set forth in SEQ ID NO. 5; and (6) the amino acid sequence of a light chain CDR3 is set forth in SEQ ID NO. 6. The monoclonal antibody 10G8 provided in the present invention can recognize the CV-A6 virus, has neutralizing activity, has a 100% protection rate in mice, and is of great significance for the treatment of diseases caused by the CV-A6 pathogen and for vaccine research.

The invention belongs to the technical field of immunity, and discloses a CpG ODN delivery system based on dextran capsule aluminum salt particles and a preparation method and application thereof. The CpG ODN delivery system comprises dextran particles GPs from yeast, an aluminum salt colloid encapsulated in cavities of the dextran particles GPs, and oligodeoxynucleotide CpG ODN adsorbed on the aluminum salt colloid through static electricity. According to the system, the immune activation effect of CpG ODN on specific immune cells such as DC is remarkably improved, so that stronger antigen-specific humoral immunity and cellular immune response is induced. The system is highly simple and convenient to operate, highly uniform in particle size and relatively safe in component, and an important innovative scheme is provided for promoting application of CpG ODN in vaccine research and development.

The invention discloses application of a micropeptide PVT149 coded by lncRNA PVT1 in preparation of influenza virus vaccines. The micropeptide involved in the scheme can remarkably promote replication of influenza viruses on the cellular level, and the virus RNA expression level and the virus load are improved; on the basis, the micropeptide PVT149 is used as a replication enhancer in the influenza virus vaccine production process, so that the virus replication efficiency and yield in vaccine research and development and production are improved, and a new technical thought and application approach are provided for research and development of influenza virus vaccines.

The invention discloses application of ixazomib in preparation of a medicine for preventing and treating Nipah virus, and belongs to the technical field of medicine. The method mainly aims at ubiquitination modification of the nipah virus M protein, the host proteasome pathway is inhibited through the ixazomib, free ubiquitination factors in cells are depleted to achieve the effect of inhibiting ubiquitination of the M protein, then nucleoplasm shuttle of the M protein is inhibited, replication of the nipah virus is inhibited, and a good effect is achieved. The ixazomib is used as a nipah virus inhibitor, belongs to a new application of an old medicine, and provides a new application for the ixazomib. And the safety of the ixazomib has no problem, so that the ixazomib can be applied clinically. In addition, at present, most of research and development of virus drugs and vaccine research are designed or modified aiming at viruses, and a new thought is provided for research and development of drugs and vaccines in the future.

The application discloses application of MY-1B in preparation of medicines for preventing and treating nipah virus, and belongs to the technical field of medicines.The application is mainly directed to m5C modification of a host, and the methyltransferase activity of NSUN2 is inhibited, so that the m5C modification of the host is reduced, and the replication of the nipah virus is inhibited, and good effects are achieved.At present, most of the researches on virus medicines and vaccines are designed or modified according to the virus itself, and the application provides a new idea for future medicine research and development and vaccine research, and also provides a new use for MY-1B.